Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
13,253
archived clinical trials in
Arthritis

A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Altoona Center for Clinical Research
2201
mi
from 91732
Duncansville, PA
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Altoona Center for Clinical Research
2201
mi
from 91732
Duncansville, PA
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
PMA Medical Specialists, LLC
2355
mi
from 91732
Limerick, PA
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
PMA Medical Specialists, LLC
2355
mi
from 91732
Limerick, PA
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Methodist Healthcare
1600
mi
from 91732
Memphis, TN
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Methodist Healthcare
1600
mi
from 91732
Memphis, TN
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Ramesh C. Gupta, M.D.
1586
mi
from 91732
Memphis, TN
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Ramesh C. Gupta, M.D.
1586
mi
from 91732
Memphis, TN
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Austin Regional Clinic
1209
mi
from 91732
Austin, TX
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Austin Regional Clinic
1209
mi
from 91732
Austin, TX
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Pioneer Research Solutions
1308
mi
from 91732
Cypress, TX
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Pioneer Research Solutions
1308
mi
from 91732
Cypress, TX
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Arthritis Care and Diagnostic Center
1224
mi
from 91732
Dallas, TX
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Arthritis Care and Diagnostic Center
1224
mi
from 91732
Dallas, TX
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Accurate Clinical Research
1357
mi
from 91732
Houston, TX
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Accurate Clinical Research
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Houston Institute for Clinical Research
1349
mi
from 91732
Houston, TX
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Houston Institute for Clinical Research
1349
mi
from 91732
Houston, TX
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Arthritis & Osteoporosis Associates, LLP
923
mi
from 91732
Lubbock, TX
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Arthritis & Osteoporosis Associates, LLP
923
mi
from 91732
Lubbock, TX
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Accurate Clinical Research, Inc.
1378
mi
from 91732
Nassau Bay, TX
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Accurate Clinical Research, Inc.
1378
mi
from 91732
Nassau Bay, TX
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Apex Clinical Research
840
mi
from 91732
Kennewick, WA
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Apex Clinical Research
840
mi
from 91732
Kennewick, WA
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Swedish Medical Center
961
mi
from 91732
Seattle, WA
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Swedish Medical Center
961
mi
from 91732
Seattle, WA
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Arthritis Northwest Rheumatology
938
mi
from 91732
Spokane, WA
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Arthritis Northwest Rheumatology
938
mi
from 91732
Spokane, WA
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Rheumatology and Immunotherapy Center
1720
mi
from 91732
Franklin, WI
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Rheumatology and Immunotherapy Center
1720
mi
from 91732
Franklin, WI
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Florida Medical Clinic
2145
mi
from 91732
Zephyrhills, FL
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Florida Medical Clinic
2145
mi
from 91732
Zephyrhills, FL
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Clinical Research Center of Reading, LLC
2331
mi
from 91732
Wyomissing, PA
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Clinical Research Center of Reading, LLC
2331
mi
from 91732
Wyomissing, PA
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Pennsylvania Regional Center for Arthritis & Osteoarthritis
2331
mi
from 91732
Wyomissing, PA
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Pennsylvania Regional Center for Arthritis & Osteoarthritis
2331
mi
from 91732
Wyomissing, PA
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
7516
mi
from 91732
Camperdown,
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
7516
mi
from 91732
Camperdown,
Click here to add this to my saved trials
Autologous Adipose-Derived Stromal Cells Delivered Intra-articularly in Patients With Osteoarthritis.
An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Intra- Articularly in Patients With Osteoarthritis
Status: Enrolling
Updated:  11/21/2017
Ageless Institute
2319
mi
from 91732
Aventura, FL
Autologous Adipose-Derived Stromal Cells Delivered Intra-articularly in Patients With Osteoarthritis.
An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Intra- Articularly in Patients With Osteoarthritis
Status: Enrolling
Updated: 11/21/2017
Ageless Institute
2319
mi
from 91732
Aventura, FL
Click here to add this to my saved trials
A Study With GLPG1972 in Osteoarthritis Subjects
Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Doses of GLPG1972 for 4 Weeks in Subjects With Osteoarthritis
Status: Enrolling
Updated:  11/21/2017
Covance-Daytona Beach
2186
mi
from 91732
Daytona Beach, FL
A Study With GLPG1972 in Osteoarthritis Subjects
Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Doses of GLPG1972 for 4 Weeks in Subjects With Osteoarthritis
Status: Enrolling
Updated: 11/21/2017
Covance-Daytona Beach
2186
mi
from 91732
Daytona Beach, FL
Click here to add this to my saved trials
Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403
An Open-label, International, Multi-center, Phase II, Extension Trial Investigating Long-term Efficacy and Safety of Repeated Treatment Courses of Ofatumumab, a Fully Human Monoclonal Anti-CD20 Antibody, in Adult Patients With Active Rheumatoid Arthritis Who Previously Received Ofatumumab or Placebo
Status: Enrolling
Updated:  11/27/2017
GSK Investigational Site
24
mi
from 91732
Los Angeles, CA
Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403
An Open-label, International, Multi-center, Phase II, Extension Trial Investigating Long-term Efficacy and Safety of Repeated Treatment Courses of Ofatumumab, a Fully Human Monoclonal Anti-CD20 Antibody, in Adult Patients With Active Rheumatoid Arthritis Who Previously Received Ofatumumab or Placebo
Status: Enrolling
Updated: 11/27/2017
GSK Investigational Site
24
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403
An Open-label, International, Multi-center, Phase II, Extension Trial Investigating Long-term Efficacy and Safety of Repeated Treatment Courses of Ofatumumab, a Fully Human Monoclonal Anti-CD20 Antibody, in Adult Patients With Active Rheumatoid Arthritis Who Previously Received Ofatumumab or Placebo
Status: Enrolling
Updated:  11/27/2017
GSK Investigational Site
2315
mi
from 91732
Fort Lauderdale, FL
Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403
An Open-label, International, Multi-center, Phase II, Extension Trial Investigating Long-term Efficacy and Safety of Repeated Treatment Courses of Ofatumumab, a Fully Human Monoclonal Anti-CD20 Antibody, in Adult Patients With Active Rheumatoid Arthritis Who Previously Received Ofatumumab or Placebo
Status: Enrolling
Updated: 11/27/2017
GSK Investigational Site
2315
mi
from 91732
Fort Lauderdale, FL
Click here to add this to my saved trials
Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403
An Open-label, International, Multi-center, Phase II, Extension Trial Investigating Long-term Efficacy and Safety of Repeated Treatment Courses of Ofatumumab, a Fully Human Monoclonal Anti-CD20 Antibody, in Adult Patients With Active Rheumatoid Arthritis Who Previously Received Ofatumumab or Placebo
Status: Enrolling
Updated:  11/27/2017
GSK Investigational Site
2435
mi
from 91732
New York, NY
Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403
An Open-label, International, Multi-center, Phase II, Extension Trial Investigating Long-term Efficacy and Safety of Repeated Treatment Courses of Ofatumumab, a Fully Human Monoclonal Anti-CD20 Antibody, in Adult Patients With Active Rheumatoid Arthritis Who Previously Received Ofatumumab or Placebo
Status: Enrolling
Updated: 11/27/2017
GSK Investigational Site
2435
mi
from 91732
New York, NY
Click here to add this to my saved trials
Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403
An Open-label, International, Multi-center, Phase II, Extension Trial Investigating Long-term Efficacy and Safety of Repeated Treatment Courses of Ofatumumab, a Fully Human Monoclonal Anti-CD20 Antibody, in Adult Patients With Active Rheumatoid Arthritis Who Previously Received Ofatumumab or Placebo
Status: Enrolling
Updated:  11/27/2017
GSK Investigational Site
2201
mi
from 91732
Duncansville, PA
Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403
An Open-label, International, Multi-center, Phase II, Extension Trial Investigating Long-term Efficacy and Safety of Repeated Treatment Courses of Ofatumumab, a Fully Human Monoclonal Anti-CD20 Antibody, in Adult Patients With Active Rheumatoid Arthritis Who Previously Received Ofatumumab or Placebo
Status: Enrolling
Updated: 11/27/2017
GSK Investigational Site
2201
mi
from 91732
Duncansville, PA
Click here to add this to my saved trials
Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403
An Open-label, International, Multi-center, Phase II, Extension Trial Investigating Long-term Efficacy and Safety of Repeated Treatment Courses of Ofatumumab, a Fully Human Monoclonal Anti-CD20 Antibody, in Adult Patients With Active Rheumatoid Arthritis Who Previously Received Ofatumumab or Placebo
Status: Enrolling
Updated:  11/27/2017
GSK Investigational Site
5582
mi
from 91732
Glostrup,
Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403
An Open-label, International, Multi-center, Phase II, Extension Trial Investigating Long-term Efficacy and Safety of Repeated Treatment Courses of Ofatumumab, a Fully Human Monoclonal Anti-CD20 Antibody, in Adult Patients With Active Rheumatoid Arthritis Who Previously Received Ofatumumab or Placebo
Status: Enrolling
Updated: 11/27/2017
GSK Investigational Site
5582
mi
from 91732
Glostrup,
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  11/28/2017
Clinical Research Facility
14
mi
from 91732
Glendale, AZ
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 11/28/2017
Clinical Research Facility
14
mi
from 91732
Glendale, AZ
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  11/28/2017
Clinical Research Facility
14
mi
from 91732
Glendale, AZ
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 11/28/2017
Clinical Research Facility
14
mi
from 91732
Glendale, AZ
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  11/28/2017
Clinical Research Facility
358
mi
from 91732
Mesa, AZ
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 11/28/2017
Clinical Research Facility
358
mi
from 91732
Mesa, AZ
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  11/28/2017
Clinical Research Facility
15
mi
from 91732
La Palma, CA
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 11/28/2017
Clinical Research Facility
15
mi
from 91732
La Palma, CA
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  11/28/2017
Clinical Research Facility
1806
mi
from 91732
Granger, IN
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 11/28/2017
Clinical Research Facility
1806
mi
from 91732
Granger, IN
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  11/28/2017
Clinical Research Facility
1573
mi
from 91732
Saint Louis, MO
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 11/28/2017
Clinical Research Facility
1573
mi
from 91732
Saint Louis, MO
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  11/28/2017
Clinical Research Facility
1573
mi
from 91732
Saint Louis, MO
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 11/28/2017
Clinical Research Facility
1573
mi
from 91732
Saint Louis, MO
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  11/28/2017
Clinical Research Facility
mi
from 91732
Orchard Park, NY
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 11/28/2017
Clinical Research Facility
mi
from 91732
Orchard Park, NY
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  11/28/2017
Clinical Research Facility
2118
mi
from 91732
Salisbury, NC
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 11/28/2017
Clinical Research Facility
2118
mi
from 91732
Salisbury, NC
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  11/28/2017
Clinical Research Facility
2025
mi
from 91732
Middleburg Heights, OH
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 11/28/2017
Clinical Research Facility
2025
mi
from 91732
Middleburg Heights, OH
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  11/28/2017
Clinical Research Facility
2200
mi
from 91732
Duncansville, PA
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 11/28/2017
Clinical Research Facility
2200
mi
from 91732
Duncansville, PA
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  11/28/2017
Clinical Research Facility
1213
mi
from 91732
Austin, TX
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 11/28/2017
Clinical Research Facility
1213
mi
from 91732
Austin, TX
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  11/28/2017
Clinical Research Facility
1357
mi
from 91732
Houston, TX
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 11/28/2017
Clinical Research Facility
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  11/28/2017
Site Reference ID/Investigator# 128791
mi
from 91732
Maroochydore,
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 11/28/2017
Site Reference ID/Investigator# 128791
mi
from 91732
Maroochydore,
Click here to add this to my saved trials
The Knee Usual Care Evaluation Study
Title: The Study of Intra-articular Interventions of Platelet Rich Plasma or Hyaluronic Acid Compounds vs. Usual Care (Exercise/Diet/Supplements) in the Medical Management of Knee OA- Effects on Pain and Function; Effects on Articular Cartilage; Effects on Time to Partial or Total Knee Arthroplasty: The Knee Usual Care Evaluation (KUCE) Study
Status: Enrolling
Updated:  11/29/2017
Hospital for Special Surgery
2434
mi
from 91732
New York, NY
The Knee Usual Care Evaluation Study
Title: The Study of Intra-articular Interventions of Platelet Rich Plasma or Hyaluronic Acid Compounds vs. Usual Care (Exercise/Diet/Supplements) in the Medical Management of Knee OA- Effects on Pain and Function; Effects on Articular Cartilage; Effects on Time to Partial or Total Knee Arthroplasty: The Knee Usual Care Evaluation (KUCE) Study
Status: Enrolling
Updated: 11/29/2017
Hospital for Special Surgery
2434
mi
from 91732
New York, NY
Click here to add this to my saved trials
Inflammation and the Heart
Inflammation and the Heart
Status: Enrolling
Updated:  11/30/2017
Vanderbilt
1762
mi
from 91732
Nashville, TN
Inflammation and the Heart
Inflammation and the Heart
Status: Enrolling
Updated: 11/30/2017
Vanderbilt
1762
mi
from 91732
Nashville, TN
Click here to add this to my saved trials
A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX
A Randomized, Double-Blind Trial Assessing the Impact of Methotrexate Discontinuation on the Efficacy of Subcutaneous Tocilizumab With Methotrexate Therapy
Status: Enrolling
Updated:  11/30/2017
Pinnacle Research Group; Llc, Central
1839
mi
from 91732
Anniston, AL
A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX
A Randomized, Double-Blind Trial Assessing the Impact of Methotrexate Discontinuation on the Efficacy of Subcutaneous Tocilizumab With Methotrexate Therapy
Status: Enrolling
Updated: 11/30/2017
Pinnacle Research Group; Llc, Central
1839
mi
from 91732
Anniston, AL
Click here to add this to my saved trials
A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX
A Randomized, Double-Blind Trial Assessing the Impact of Methotrexate Discontinuation on the Efficacy of Subcutaneous Tocilizumab With Methotrexate Therapy
Status: Enrolling
Updated:  11/30/2017
Uni Of Alabama,Birmingham; Medicine - Rheumatology
1785
mi
from 91732
Birmingham, AL
A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX
A Randomized, Double-Blind Trial Assessing the Impact of Methotrexate Discontinuation on the Efficacy of Subcutaneous Tocilizumab With Methotrexate Therapy
Status: Enrolling
Updated: 11/30/2017
Uni Of Alabama,Birmingham; Medicine - Rheumatology
1785
mi
from 91732
Birmingham, AL
Click here to add this to my saved trials
A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX
A Randomized, Double-Blind Trial Assessing the Impact of Methotrexate Discontinuation on the Efficacy of Subcutaneous Tocilizumab With Methotrexate Therapy
Status: Enrolling
Updated:  11/30/2017
Rheumatology Associates Of North Alabama, P.C.
1784
mi
from 91732
Huntsville, AL
A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX
A Randomized, Double-Blind Trial Assessing the Impact of Methotrexate Discontinuation on the Efficacy of Subcutaneous Tocilizumab With Methotrexate Therapy
Status: Enrolling
Updated: 11/30/2017
Rheumatology Associates Of North Alabama, P.C.
1784
mi
from 91732
Huntsville, AL
Click here to add this to my saved trials
A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX
A Randomized, Double-Blind Trial Assessing the Impact of Methotrexate Discontinuation on the Efficacy of Subcutaneous Tocilizumab With Methotrexate Therapy
Status: Enrolling
Updated:  11/30/2017
Clnical & Translational Reseach Center for Alabama, PC
1749
mi
from 91732
Tuscaloosa, AL
A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX
A Randomized, Double-Blind Trial Assessing the Impact of Methotrexate Discontinuation on the Efficacy of Subcutaneous Tocilizumab With Methotrexate Therapy
Status: Enrolling
Updated: 11/30/2017
Clnical & Translational Reseach Center for Alabama, PC
1749
mi
from 91732
Tuscaloosa, AL
Click here to add this to my saved trials
A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX
A Randomized, Double-Blind Trial Assessing the Impact of Methotrexate Discontinuation on the Efficacy of Subcutaneous Tocilizumab With Methotrexate Therapy
Status: Enrolling
Updated:  11/30/2017
Arizona Arthritis & Rheumatology Associates, PC
336
mi
from 91732
Glendale, AZ
A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX
A Randomized, Double-Blind Trial Assessing the Impact of Methotrexate Discontinuation on the Efficacy of Subcutaneous Tocilizumab With Methotrexate Therapy
Status: Enrolling
Updated: 11/30/2017
Arizona Arthritis & Rheumatology Associates, PC
336
mi
from 91732
Glendale, AZ
Click here to add this to my saved trials
A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX
A Randomized, Double-Blind Trial Assessing the Impact of Methotrexate Discontinuation on the Efficacy of Subcutaneous Tocilizumab With Methotrexate Therapy
Status: Enrolling
Updated:  11/30/2017
Arizona Arthritis & Rheumatology Research, PLLC
355
mi
from 91732
Mesa, AZ
A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX
A Randomized, Double-Blind Trial Assessing the Impact of Methotrexate Discontinuation on the Efficacy of Subcutaneous Tocilizumab With Methotrexate Therapy
Status: Enrolling
Updated: 11/30/2017
Arizona Arthritis & Rheumatology Research, PLLC
355
mi
from 91732
Mesa, AZ
Click here to add this to my saved trials
A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX
A Randomized, Double-Blind Trial Assessing the Impact of Methotrexate Discontinuation on the Efficacy of Subcutaneous Tocilizumab With Methotrexate Therapy
Status: Enrolling
Updated:  11/30/2017
Arizona Arthritis and Rheuma
355
mi
from 91732
Mesa, AZ
A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX
A Randomized, Double-Blind Trial Assessing the Impact of Methotrexate Discontinuation on the Efficacy of Subcutaneous Tocilizumab With Methotrexate Therapy
Status: Enrolling
Updated: 11/30/2017
Arizona Arthritis and Rheuma
355
mi
from 91732
Mesa, AZ
Click here to add this to my saved trials
A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX
A Randomized, Double-Blind Trial Assessing the Impact of Methotrexate Discontinuation on the Efficacy of Subcutaneous Tocilizumab With Methotrexate Therapy
Status: Enrolling
Updated:  11/30/2017
Valley Arthritis Care, LLC
343
mi
from 91732
Phoenix, AZ
A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX
A Randomized, Double-Blind Trial Assessing the Impact of Methotrexate Discontinuation on the Efficacy of Subcutaneous Tocilizumab With Methotrexate Therapy
Status: Enrolling
Updated: 11/30/2017
Valley Arthritis Care, LLC
343
mi
from 91732
Phoenix, AZ
Click here to add this to my saved trials